28 related articles for article (PubMed ID: 18095031)
1. Identifying and Validating of an Autophagy-Related Gene Signature for the Prediction of Early Relapse in Breast Cancer.
Min Y; Feng Y; Luo H; Hu D; Wei X; He D; Yin G; Fan S
Front Endocrinol (Lausanne); 2022; 13():824362. PubMed ID: 35250881
[TBL] [Abstract][Full Text] [Related]
2. Association of GSTP1 p.Ile105Val (rs1695, c.313A > G) Variant with the Risk of Breast Carcinoma among Egyptian Women.
Youssef MM; Elsaid AM; El-Saeed RA; Mukhlif RT; Megahed H; Al-Alawy AI; Elshazli RM
Biochem Genet; 2021 Dec; 59(6):1487-1505. PubMed ID: 33939082
[TBL] [Abstract][Full Text] [Related]
3. Significant association between ERCC2 and MTHR polymorphisms and breast cancer susceptibility in Moroccan population: genotype and haplotype analysis in a case-control study.
Hardi H; Melki R; Boughaleb Z; El Harroudi T; Aissaoui S; Boukhatem N
BMC Cancer; 2018 Mar; 18(1):292. PubMed ID: 29544444
[TBL] [Abstract][Full Text] [Related]
4.
Ma J; Zhu SL; Liu Y; Huang XY; Su DK
Oncotarget; 2017 Sep; 8(42):72939-72949. PubMed ID: 29069838
[TBL] [Abstract][Full Text] [Related]
5. GSTT1 and GSTM1 polymorphisms predict treatment outcome for breast cancer: a systematic review and meta-analysis.
Hu XY; Huang XY; Ma J; Zuo Y; Luo NB; Lai SL; Su DK
Tumour Biol; 2016 Jan; 37(1):151-62. PubMed ID: 26577857
[TBL] [Abstract][Full Text] [Related]
6. MTHFR 677C>T polymorphism and the risk of breast cancer: evidence from an original study and pooled data for 28031 cases and 31880 controls.
Pooja S; Carlus J; Sekhar D; Francis A; Gupta N; Konwar R; Kumar S; Kumar S; Thangaraj K; Rajender S
PLoS One; 2015; 10(3):e0120654. PubMed ID: 25803740
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetic influence of GST polymorphisms on anthracycline-based chemotherapy responses and toxicity in breast cancer patients: a multi-analytical approach.
Tulsyan S; Chaturvedi P; Agarwal G; Lal P; Agrawal S; Mittal RD; Mittal B
Mol Diagn Ther; 2013 Dec; 17(6):371-9. PubMed ID: 23812950
[TBL] [Abstract][Full Text] [Related]
8. Functional polymorphisms in xenobiotic metabolizing enzymes and their impact on the therapy of breast cancer.
Vianna-Jorge R; Festa-Vasconcellos JS; Goulart-Citrangulo SM; Leite MS
Front Genet; 2012; 3():329. PubMed ID: 23346096
[TBL] [Abstract][Full Text] [Related]
9. A literature review of MTHFR (C677T and A1298C polymorphisms) and cancer risk.
Izmirli M
Mol Biol Rep; 2013 Jan; 40(1):625-37. PubMed ID: 23076526
[TBL] [Abstract][Full Text] [Related]
10. Roles of ABCB1 gene polymorphisms and haplotype in susceptibility to breast carcinoma risk and clinical outcomes.
Wu H; Kang H; Liu Y; Tong W; Liu D; Yang X; Lian M; Yao W; Zhao H; Huang D; Sha X; Wang E; Wei M
J Cancer Res Clin Oncol; 2012 Sep; 138(9):1449-62. PubMed ID: 22526155
[TBL] [Abstract][Full Text] [Related]
11. Translational medicine and reliability of single-nucleotide polymorphism studies: can we believe in SNP reports or not?
Valachis A; Mauri D; Neophytou C; Polyzos NP; Tsali L; Garras A; Papanikolau EG
Int J Med Sci; 2011; 8(6):492-500. PubMed ID: 21897762
[TBL] [Abstract][Full Text] [Related]
12. The prevalence and assessment of ErbB2-positive breast cancer in Asia: a literature survey.
Tan YO; Han S; Lu YS; Yip CH; Sunpaweravong P; Jeong J; Caguioa PB; Aggarwal S; Yeoh EM; Moon H
Cancer; 2010 Dec; 116(23):5348-57. PubMed ID: 20715159
[TBL] [Abstract][Full Text] [Related]
13. Influence of thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms on the disease-free survival of breast cancer patients receiving adjuvant 5-fluorouracil/methotrexate-based therapy.
Paré L; Altés A; Ramón y Cajal T; Del Rio E; Alonso C; Sedano L; Barnadas A; Baiget M
Anticancer Drugs; 2007 Aug; 18(7):821-5. PubMed ID: 17581305
[TBL] [Abstract][Full Text] [Related]
14. The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population.
Huang ZH; Hua D; Li LH
Cancer Chemother Pharmacol; 2009 Apr; 63(5):911-8. PubMed ID: 18704422
[TBL] [Abstract][Full Text] [Related]
15. TYMS, MTHFR, p53 and MDR1 gene polymorphisms in breast cancer patients treated with adjuvant therapy.
Henríquez-Hernández LA; Pérez LF; Hernández AG; de León AC; Díaz-Chico B; Rosales AM
Cancer Epidemiol; 2010 Aug; 34(4):490-3. PubMed ID: 20371218
[TBL] [Abstract][Full Text] [Related]
16. Methylenetetrahydrofolate reductase and thymidylate synthase polymorphisms are not associated with breast cancer risk or phenotype.
Grieu F; Powell B; Beilby J; Iacopetta B
Anticancer Res; 2004; 24(5B):3215-9. PubMed ID: 15510613
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics of stomach cancer.
Toffoli G; Cecchin E
Suppl Tumori; 2003; 2(5):S19-22. PubMed ID: 12914384
[TBL] [Abstract][Full Text] [Related]
18. Multiple Genetic Polymorphisms of GSTP1 313AG, MDR1 3435CC, and MTHFR 677CC highly correlated with early relapse of breast cancer patients in Taiwan.
Huang MY; Wang YH; Chen FM; Lee SC; Fang WY; Cheng TL; Hou MF; Wang JY; Lin SR
Ann Surg Oncol; 2008 Mar; 15(3):872-80. PubMed ID: 18095031
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
